The 57th China International Pharmaceutical API, Intermediates, Packaging, Equipment Autumn Fair (API CHINA) was held on the 15th to 17th at the Qingdao International Convention and Exhibition Center. Representatives of purchasing delegations from various countries and regions are invited to attend the meeting to provide exhibitors with more business opportunities for exchanges and cooperation. The highlight of this exhibition is that Sinopharm Reed Exhibitions cooperated with the World Pharmaceutical Industry Exhibition (INTERPHEX) to set up the Interpex International (APIF) in this APICHINA to exchange the Chinese pharmaceutical industry with the international pharmaceutical industry. Provide good opportunities.
“The current pharmaceutical industry seems to be undergoing a baptism, especially for pharmaceutical companies, facing a severe test.†The 57th China International Pharmaceutical API, Intermediates, Packaging and Equipment Autumn Trading on the November 17th Sunset Screen At the meeting (API China), Shen Xianji, vice president of the China Chemical Pharmaceutical Industry Association, said in the report.
The overall situation of the preparation is not optimistic
According to statistics released by the National Bureau of Statistics, there is still a big gap between the economic benefits of the chemical pharmaceutical industry and the national industrial situation from January to September 2006.
From January to September, the profits of industrial enterprises above designated size increased by 29.6%, while the chemical and pharmaceutical industries only increased by 4.6%, of which the preparation sub-sector (referring to the collection of pharmaceutical raw materials without chemical raw material production) decreased by 3.8% year-on-year; the national industrial product sales revenue 16.3% year-on-year increase, chemical and pharmaceutical industries increased by 15.2% year-on-year; industrial enterprises above designated size reached 19.9%, losses totaled 25.7% year-on-year, chemical and pharmaceutical industries suffered losses 27.1%, and manufacturing sub-sector losses reached 30.8% It is nearly 11 percentage points higher than the national average. Only the losses of loss-making enterprises grew at a rate lower than the national average of 9.7%, and the amount of losses in the sub-sector of the manufacturing industry increased by 24.1% year-on-year.
According to the completion of the economic indicators of the national key pharmaceutical industry companies collected by the Statistical Pharmaceuticals and Pharmaceuticals Association's Statistical Cooperation Committee, although the decline in the profits in the two months of September and September slowed, it rose by 37.6% from July, the largest decline in the whole year. Shen Xianji frankly stated that the overall situation is still not optimistic. Since the situation from January to September, the total profit of key enterprises decreased by 12.9% year-on-year, and the increase in profits fell by 19.09% over the same period.
In 2006, the pharmaceutical industry experienced policy adjustments, and the market itself was also "shuffled." Of the 147 companies that collected data from the Chemical and Pharmaceutical Industry Association, 32 companies suffered losses from January to September, accounting for 21.77%, and the amount of losses increased by 48 million yuan or 21.86% over the same period. Compared with the 16.8% increase in the loss in the first half of the year, the loss from January to September increased by another 5 percentage points. However, with the increase in losses, from January to September, there were 21 companies with 147 corporate profits that had grown more than 30% year-on-year, including many companies with profits of more than 100 million yuan.
For the above-mentioned grim situation, some experts believe that in order to survive in a difficult situation, enterprises must be market-oriented, pay attention to research and development, attach importance to product quality and market promotion, in order to stand out in the harsh competition.
A fact also proves that companies are seeking innovation in the face of unfavorable policy environment and market environment. According to the data released by the Association of Chemical and Pharmaceutical Industry, in the first half of 2006, when the output of ordinary tablets dropped by 12%, sustained-release and controlled-release tablets increased by 28%, indicating that companies are making great efforts to improve the preparation technology. And achieved initial results.
Increase in export volume of bulk drugs
In the first half of 2006, the export situation of the 24 categories of chemical raw material drugs remained positive, but affected by the sales of domestic preparations, the output was 240,000 tons, only a 5% increase year-on-year, 11.8% lower than the increase of the same period of last year; the supply of exports completed 115,000 Ton, an increase of 13% year-on-year, an increase of 5.6% from the increase in the same period of last year, the proportion of supply exports to production was 47.8%, compared with 44.9% in the same period of last year.
Exports of macrolides and cephalosporins in anti-infective drugs maintained a relatively high growth rate in the first half of this year, at 45.9% and 38.7%, respectively. Exports of antipyretic and analgesic products showed encouraging growth. Exports grew 23.4 in the first half of the year. In addition to aspirin and metamizol, exports of other varieties have maintained double-digit growth; among vitamins, the export situation of vitamin B family has maintained a good trend in the first half of the year, of which exports of vitamin B1 increased by 277%. The growth also led to an increase in production. Vitamin B1 production increased by 163% in the first half of the year. VC remained sluggish. In the first half of the year, exports fell by 14.3%. In addition to individual varieties of antibiotics, the export situation in the first half of the year was also Very good, the export of 6-APA increased by 119.3%, the cefazolin acid increased by 230.35%, and the 7-ADCA increased by 341.9%.
Of the 49 key imported products, 37 were imported in the first half of the year, and the import value was 150 million yuan, a decrease of 23.23% year-on-year. It is worth mentioning that, with the introduction and improvement of production technology, most of the raw materials for cephalosporins in China have been converted from imported to exported. Of the 15 key cephalosporins, only 10 were imported in the first half of this year, and the import volume of 5 of them fell year-on-year.
There are also some phenomena worthy of deep reflection in the industry. According to the customs data of 67 key export products, in the first half of 2006, the cumulative amount of customs exports was US$1.4 billion, an increase of 16.41% compared with the same period of the previous year, an increase of 2.8 percentage points, and the increase in export value did not show the same amount as exports. The rate of increase.
According to the change in the unit price of 54 kinds of APIs announced by the Association of Chemical and Pharmaceutical Industry, the average unit price of 32 export varieties in the first half of 2006 decreased compared with last year, with an average decrease of 14.39%, and most of them were bulk APIs. The biggest drop in price was ampicillin, which was 62.39%. In addition, the increase in the average unit price of all four varieties was below 1%, and the price of vitamin B2 and its derivatives was the largest, which was 22.78%.
Increase the promotion of generic drugs
In response to these gaps, this year the Chemical and Pharmaceutical Industry Association has conducted written research. Shen Yinji summarized the following opinions: First, R&D investment disparities. In 2004, the world's pharmaceutical industry R&D investment accounted for 15.7% of sales, and China accounted for only 0.89%. 2005 Yearly growth, but only 1.02%, and the absolute amount is small, investment is decentralized, and the establishment of an innovation system has become a long-term task for innovative countries; Second, the entire production process is not strictly controlled, as in the implementation of GMP Light hardware and software, remodeling and light processes, and heavy inspections are relatively common. Third, the production process of the products is backward, the quality standards are not high, and there are many irregularities in the production of new drugs, and it is difficult to export products. In order to change the only way out of this phenomenon, Shen Xianji believes that it should aim at the high standards of similar products of the world, improve technology, improve quality, and participate in the competition in the international pharmaceutical market. Fourth, high resource consumption and environmental protection owed more debts. To build a conservation-oriented society and change the mode of economic growth, we must vigorously promote the reform of resource prices.
Based on the actual situation in China, Shen Xianji suggested that in the period to come, the government should increase its efforts to promote generic drugs and encourage the production of generic drugs. At the same time, it should also increase investment in R&D. In particular, relevant supporting policies should be introduced. Industrialization of R&D achievements. At the same time, companies should also consider their market advantages in terms of market demand, efficacy and safety, and differentiation from similar products, and gradually develop their own advantages in competition.
“The current pharmaceutical industry seems to be undergoing a baptism, especially for pharmaceutical companies, facing a severe test.†The 57th China International Pharmaceutical API, Intermediates, Packaging and Equipment Autumn Trading on the November 17th Sunset Screen At the meeting (API China), Shen Xianji, vice president of the China Chemical Pharmaceutical Industry Association, said in the report.
The overall situation of the preparation is not optimistic
According to statistics released by the National Bureau of Statistics, there is still a big gap between the economic benefits of the chemical pharmaceutical industry and the national industrial situation from January to September 2006.
From January to September, the profits of industrial enterprises above designated size increased by 29.6%, while the chemical and pharmaceutical industries only increased by 4.6%, of which the preparation sub-sector (referring to the collection of pharmaceutical raw materials without chemical raw material production) decreased by 3.8% year-on-year; the national industrial product sales revenue 16.3% year-on-year increase, chemical and pharmaceutical industries increased by 15.2% year-on-year; industrial enterprises above designated size reached 19.9%, losses totaled 25.7% year-on-year, chemical and pharmaceutical industries suffered losses 27.1%, and manufacturing sub-sector losses reached 30.8% It is nearly 11 percentage points higher than the national average. Only the losses of loss-making enterprises grew at a rate lower than the national average of 9.7%, and the amount of losses in the sub-sector of the manufacturing industry increased by 24.1% year-on-year.
According to the completion of the economic indicators of the national key pharmaceutical industry companies collected by the Statistical Pharmaceuticals and Pharmaceuticals Association's Statistical Cooperation Committee, although the decline in the profits in the two months of September and September slowed, it rose by 37.6% from July, the largest decline in the whole year. Shen Xianji frankly stated that the overall situation is still not optimistic. Since the situation from January to September, the total profit of key enterprises decreased by 12.9% year-on-year, and the increase in profits fell by 19.09% over the same period.
In 2006, the pharmaceutical industry experienced policy adjustments, and the market itself was also "shuffled." Of the 147 companies that collected data from the Chemical and Pharmaceutical Industry Association, 32 companies suffered losses from January to September, accounting for 21.77%, and the amount of losses increased by 48 million yuan or 21.86% over the same period. Compared with the 16.8% increase in the loss in the first half of the year, the loss from January to September increased by another 5 percentage points. However, with the increase in losses, from January to September, there were 21 companies with 147 corporate profits that had grown more than 30% year-on-year, including many companies with profits of more than 100 million yuan.
For the above-mentioned grim situation, some experts believe that in order to survive in a difficult situation, enterprises must be market-oriented, pay attention to research and development, attach importance to product quality and market promotion, in order to stand out in the harsh competition.
A fact also proves that companies are seeking innovation in the face of unfavorable policy environment and market environment. According to the data released by the Association of Chemical and Pharmaceutical Industry, in the first half of 2006, when the output of ordinary tablets dropped by 12%, sustained-release and controlled-release tablets increased by 28%, indicating that companies are making great efforts to improve the preparation technology. And achieved initial results.
Increase in export volume of bulk drugs
In the first half of 2006, the export situation of the 24 categories of chemical raw material drugs remained positive, but affected by the sales of domestic preparations, the output was 240,000 tons, only a 5% increase year-on-year, 11.8% lower than the increase of the same period of last year; the supply of exports completed 115,000 Ton, an increase of 13% year-on-year, an increase of 5.6% from the increase in the same period of last year, the proportion of supply exports to production was 47.8%, compared with 44.9% in the same period of last year.
Exports of macrolides and cephalosporins in anti-infective drugs maintained a relatively high growth rate in the first half of this year, at 45.9% and 38.7%, respectively. Exports of antipyretic and analgesic products showed encouraging growth. Exports grew 23.4 in the first half of the year. In addition to aspirin and metamizol, exports of other varieties have maintained double-digit growth; among vitamins, the export situation of vitamin B family has maintained a good trend in the first half of the year, of which exports of vitamin B1 increased by 277%. The growth also led to an increase in production. Vitamin B1 production increased by 163% in the first half of the year. VC remained sluggish. In the first half of the year, exports fell by 14.3%. In addition to individual varieties of antibiotics, the export situation in the first half of the year was also Very good, the export of 6-APA increased by 119.3%, the cefazolin acid increased by 230.35%, and the 7-ADCA increased by 341.9%.
Of the 49 key imported products, 37 were imported in the first half of the year, and the import value was 150 million yuan, a decrease of 23.23% year-on-year. It is worth mentioning that, with the introduction and improvement of production technology, most of the raw materials for cephalosporins in China have been converted from imported to exported. Of the 15 key cephalosporins, only 10 were imported in the first half of this year, and the import volume of 5 of them fell year-on-year.
There are also some phenomena worthy of deep reflection in the industry. According to the customs data of 67 key export products, in the first half of 2006, the cumulative amount of customs exports was US$1.4 billion, an increase of 16.41% compared with the same period of the previous year, an increase of 2.8 percentage points, and the increase in export value did not show the same amount as exports. The rate of increase.
According to the change in the unit price of 54 kinds of APIs announced by the Association of Chemical and Pharmaceutical Industry, the average unit price of 32 export varieties in the first half of 2006 decreased compared with last year, with an average decrease of 14.39%, and most of them were bulk APIs. The biggest drop in price was ampicillin, which was 62.39%. In addition, the increase in the average unit price of all four varieties was below 1%, and the price of vitamin B2 and its derivatives was the largest, which was 22.78%.
Increase the promotion of generic drugs
In response to these gaps, this year the Chemical and Pharmaceutical Industry Association has conducted written research. Shen Yinji summarized the following opinions: First, R&D investment disparities. In 2004, the world's pharmaceutical industry R&D investment accounted for 15.7% of sales, and China accounted for only 0.89%. 2005 Yearly growth, but only 1.02%, and the absolute amount is small, investment is decentralized, and the establishment of an innovation system has become a long-term task for innovative countries; Second, the entire production process is not strictly controlled, as in the implementation of GMP Light hardware and software, remodeling and light processes, and heavy inspections are relatively common. Third, the production process of the products is backward, the quality standards are not high, and there are many irregularities in the production of new drugs, and it is difficult to export products. In order to change the only way out of this phenomenon, Shen Xianji believes that it should aim at the high standards of similar products of the world, improve technology, improve quality, and participate in the competition in the international pharmaceutical market. Fourth, high resource consumption and environmental protection owed more debts. To build a conservation-oriented society and change the mode of economic growth, we must vigorously promote the reform of resource prices.
Based on the actual situation in China, Shen Xianji suggested that in the period to come, the government should increase its efforts to promote generic drugs and encourage the production of generic drugs. At the same time, it should also increase investment in R&D. In particular, relevant supporting policies should be introduced. Industrialization of R&D achievements. At the same time, companies should also consider their market advantages in terms of market demand, efficacy and safety, and differentiation from similar products, and gradually develop their own advantages in competition.
High precision double side surface grinding or fine grinding is a super finishing process performed by removing material from two surfaces of a component resulting in extremely precise geometric accuracy and surface finish. Typically, it is the last grinding step of a mechanical production chain utilized to improve and/or correct the geometry of parts coming from sintering, sawing, molding or similar operations. Depending on the application, the stock removal also can be taken from just one surface.
GMM1200 Double Side Surface Grinding Machine
Disc Grinder,High Precision Surface Grinding Machine,Precision Surface Grinder,Oil Nozzle Surface Grinding Machine
Xinxiang SKF machinery Co., Ltd. , https://www.finegrindingmachine.com